RPC1063, an experimental oral immunomodulator, is looking promising as it progresses through clinical testing. At the ACTRIMS-ECTRIMS meeting in September, Amit Bar-Or presented results of the phase 2 trial suggesting the drug is as effective as and safer than its counterpart, fingolimod.

The International MS Genetics consortium recently identified more than 45 new genetic variants associated with susceptibility to multiple sclerosis, many of which are involved in brain function